biote Corp.
NASDAQ · us_market
No AI summary generated yet for this ticker.
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.
Biote reaffirmed its full year 2026 guidance for revenue above $190 million, Adjusted EBITDA above $38 million, and a return to procedure revenue growth in the second half of this year.
Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief Financial Officer and
Moby summary of biote Corp.'s Q1 2026 earnings call
Discover why small-cap indexes lag large caps and how active screening with an enhanced Magic Formula can uncover small-cap value and manage riskâread now.
biote Corp. (BTMD) Q1 2026 Earnings Call May 6, 2026 5:00 PM EDTCompany ParticipantsBret Christensen - CEO & DirectorRobert Peterson - CFO & Chief...
Presentation Operator MessageOperator Good day, and welcome to the Biote First Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would now...
biote (NASDAQ:BTMD) executives said a voluntary recall of certain bioidentical hormone pellet inventory created a temporary but meaningful headwind in the company’s first quarter of 2026, impacting procedure revenue, margins, and salesforce productivity while management works to restore supply conti
biote Corp. (BTMD) delivered earnings and revenue surprises of -33.33% and -2.71%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Biote (BTMD) reported Q1 2026 revenue of $44.9M, missing estimates due to a product recall, but EPS of $0.06 beat forecasts. Shares fell 2.7% after-hours.
Sales team expansion on track and nearing targeted levelReturn to procedure growth expected in second half of 2026First Quarter 2026 Financial HighlightsRevenue of $44.9 millionGross...
Biote (NASDAQ:BTMD) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 83.78 percent decrease over earnings of $0.37 per share from the same period
Biote’s fair value estimate has been trimmed from US$3.17 to US$2.97 per share, signaling a tighter view on what analysts currently think the stock is worth. That change lines up with recent commentary, where many analysts are lowering price targets into a US$2 to US$3 range while balancing recall related challenges against progress on sales execution and clinic growth efforts. Read on to see how these shifting targets fit into the broader biote story and what to watch as the narrative...
GE HealthCare (GEHC) delivered earnings and revenue surprises of -7.04% and +1.52%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
IRVING, Texas, April 22, 2026--biote Corp. (Nasdaq: BTMD) ("Biote" or the "Company"), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners’ patients, today announced the Company will provide first quarter financial results on Wednesday, May 6, 2026, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET. the same day.
Truist Securities analyst Gregory Fraser maintains Biote (NASDAQ:BTMD) with a Buy and lowers the price target from $5 to $4.
biote’s modeled fair value has been trimmed from about US$4.21 to about US$3.17, a cut of roughly 25% that reflects a cooler view on what the shares may be worth today. Analysts link this reset to near term operational and growth headwinds, even as they point to stronger recent sales and EBITDA and ongoing investments aimed at future expansion. As you read on, you will see how this evolving narrative, from cautious guides to longer term themes, can shape the way you track biote from...
biote’s modeled fair value has been trimmed from about US$4.21 to about US$3.17, a cut of roughly 25% that reflects a cooler view on what the shares may be worth today. Analysts link this reset to near term operational and growth headwinds, even as they point to stronger recent sales and EBITDA and ongoing investments aimed at future expansion. As you read on, you will see how this evolving narrative, from cautious guides to longer term themes, can shape the way you track biote from...
B. Riley Securities analyst Jeff Van Sinderen maintains Biote (NASDAQ:BTMD) with a Neutral and lowers the price target from $3 to $2.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 647.0K | $873.39K | 0.00% | Added+7.8% | 2026-03-31 |
| RenTech | quant | 265.9K | $358.99K | 0.00% | Added+30.6% | 2026-03-31 |
| FidelityFMR | fundamental | 29.6K | $40.02K | 0.00% | Added+67.4% | 2026-03-31 |
| TRowePrice | fundamental | 14.8K | $21 | 0.00% | Unchanged | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | 0.08 | — | — |
| 2026-05-06 | 0.08 | 0.08 | -2.12% |
| 2026-03-11 | 0.10 | 0.07 | -29.80% |
| 2025-11-05 | 0.12 | 0.18 | +48.08% |
| 2025-08-06 | 0.13 | 0.16 | +26.52% |
| 2025-05-07 | 0.13 | 0.14 | +4.38% |
| 2025-03-12 | 0.17 | 0.37 | +117.71% |
| 2024-11-12 | 0.20 | 0.18 | -11.50% |
| 2024-08-08 | 0.26 | 0.32 | +21.19% |
| 2024-05-07 | 0.10 | 0.32 | +222.20% |
| 2024-03-12 | 0.10 | 0.10 | +1.02% |
| 2023-11-07 | 0.08 | 0.25 | +233.33% |
| 2023-08-10 | 0.10 | -0.25 | -358.61% |
| 2023-05-09 | 0.09 | -0.39 | -533.33% |
| 2023-03-28 | 0.14 | 0.18 | +28.57% |
| 2022-11-14 | 0.14 | -1.74 | -1388.89% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BTMD | -8.68% | -5.21% | -23.08% | -42.20% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -11.64% | -0.58% | -19.63% | -54.89% |